首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in han chinese patients with non valvular atrial fibrillation
【24h】

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in han chinese patients with non valvular atrial fibrillation

机译:从CYP4F2,CYP2C9和VKORC1多态性及临床变量预测华法林剂量的新算法:在中国非瓣膜性心房颤动患者中的推导

获取原文
获取原文并翻译 | 示例
           

摘要

Few pharmacogenomic dosing regimens of warfarin have been developed for Chinese patients with non valvular atrial fibrillation (NVAF). The objective of this study was to develop a new algorithm by polymorphisms of CYP2C9, VKORC1 and CYP4F2 to predict the daily stable dose of warfarin in Chinese patients with NVAF. A total of 325 Chinese NVAF patients on stable dose of warfarin with a target international normalised ratio of 1.5 to 3.0 were recruited and divided randomly into two cohorts. CYP2C9*3, VKORC1 -1639, VKORC1 1173 and CYP4F2 were detected by ligase detection reaction method. The new algorithm was developed with multivariate linear regression in cohort 1 (260 patients) and assessed with Pearson Correlation Analysis (PCA) in cohort 2 (65 patients). From 260 enrolled patients, the model (R 2 = 51.7%) was developed as: Dose = 3.47 - 0.022 (AGE) + 0.017 (WT) + 0.189 (PTE) - 0.283 (β-blocker) - 0.471 (AMIO) - 0.586 (CYP2C9 *1/*3) - 0.296 (VKORC1 CT) - 0.648 (VKORC1 TT) + 0.219 (CYP4F2 TT). PCA displayed that the algorithm was good (r = 0.658). The residual plots revealed that the predicted doses by the algorithm tend to be overestimated when lower doses were administered to patients and to be underestimated in higher doses. The algorithm developed by us might predict warfarin dose used by Chinese NVAF patients.
机译:对于中国非瓣膜性心房颤动(NVAF)患者,很少开发华法林的药物基因组学给药方案。这项研究的目的是通过CYP2C9,VKORC1和CYP4F2多态性开发一种新算法,以预测中国NVAF患者的华法林每日稳定剂量。总共招募了325名中国稳定型华法林的NVAF患者,目标国际标准化比率为1.5:3.0,并随机分为两组。通过连接酶检测反应法检测CYP2C9 * 3,VKORC1 -1639,VKORC1 1173和CYP4F2。在队列1(260例患者)中开发了具有多元线性回归的新算法,并在队列2(65例患者)中采用了Pearson相关分析(PCA)进行了评估。从260名入组患者中,模型开发为(R 2 = 51.7%)为:剂量= 3.47-0.022(AGE)+ 0.017(WT)+ 0.189(PTE)-0.283(β-受体阻滞剂)-0.471(AMIO)-0.586 (CYP2C9 * 1 / * 3)-0.296(VKORC1 CT)-0.648(VKORC1 TT)+ 0.219(CYP4F2 TT)。 PCA显示算法很好(r = 0.658)。残差图显示,当对患者使用较低剂量时,该算法的预测剂量往往被高估,而在较高剂量下则被低估了。我们开发的算法可能会预测中国NVAF患者使用的华法林剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号